View Exam | PowerPak

1. Overactive Bladder is not linked to:

A. Structural changes in the urinary tract system B. Altered neurotransmitter function C. Caffeine use D. Statin use

2. Treatment failure for Overactive Bladder:

A. Is uncommon B. Is primarily due to the cost of OAB medications C. Is primarily due to lack of aggressive dosing D. Lack of time during office visits for thorough assessment

3. Overactive Bladder is:

A. A straightforward objective diagnosis B. Relatively easy to manage with treatment algorithms C. Not influenced by other medical conditions D. A syndrome

4. Medication(s) known to contribute to Overactive Bladder include:

A. Acetaminophen B. Rivaroxaban C. Calcium Channel Blockers D. Guaifenesin

5. First-Line pharmacological treatment per AUA Guidelines for OAB include:

A. Onabotulinumtoxin A B. Interdetrusor Capsaicin injection C. Long Acting Oxybutynin D. Short acting Tolterodine

6. The anti-muscarinic bladder medication least likely to cross the blood brain barrier is:

A. Darifenacin B. Trospium C. Solifenacin D. Oxybutynin

7. Mirabegron, a beta 3 agonist OAB medication, works by:

A. Increasing the bladder's urine storage capacity B. Acting as an antagonist at the bladder activating structures in the brain C. Indirectly increasing sensitivity of muscarinic receptors to acetylcholine D. Acting as an agonist at the bladder thus activating structures in the brain

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Overactive Bladder is not linked to:

2. Treatment failure for Overactive Bladder:

3. Overactive Bladder is:

4. Medication(s) known to contribute to Overactive Bladder include:

5. First-Line pharmacological treatment per AUA Guidelines for OAB include:

6. The anti-muscarinic bladder medication least likely to cross the blood brain barrier is:

7. Mirabegron, a beta 3 agonist OAB medication, works by:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Overactive Bladder is not linked to:

2. Treatment failure for Overactive Bladder:

3. Overactive Bladder is:

4. Medication(s) known to contribute to Overactive Bladder include:

5. First-Line pharmacological treatment per AUA Guidelines for OAB include:

6. The anti-muscarinic bladder medication least likely to cross the blood brain barrier is:

7. Mirabegron, a beta 3 agonist OAB medication, works by:

« Return to Activity

Customers who Purchased
this Activity also Purchased